PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3646.1001-013	APPLICATION NO. Con't. of 10/134,314	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR James A. Shayman	FILING DATE April 15, 2004	,
April 15, 2004 (Use several sheets if necessary)	EXAMINER Janet L. Coppins	CONFIRMATION NO. GROUP	

	U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL .	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	
\mathcal{H}	AA	5,916,911	06-29-1999	Shayman et al.	
	AB	5,945,442	08-31-1999	Shayman et al.	
	AC	5,952,370	09-14-1999	Shayman et al.	
	AD	6,030,995	02-29-2000	Shayman et al.	
	AE	6,040,332	03-21-2000	Shayman et al.	
He	₽F	6,051,598	04-18-2000	Shayman et al.	
	AG				
	AH	,		·	
<u> </u>	AJ				
:	AJ		N :		
	AK	· · ·			
	AA2				
	AB2				
	AC2			·	
-	AD2		·		
	AE2				
	AF2			j.	
	AG2				
	AH2				
	AI2		_		
	AJ2				
	AK2				
	AA3				
	AB3				
	AC3.				

			<u> </u>	
EXAMINER		7	DATE CONSIDERED (1)	
	bot on	(p).	9/2/05	
			1//03	
@PFDesktop\::ODMA/MH	ODMA/HBSR05;iManage	;4671 79 ;1		===

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3646.1001-013	APPLICATION NO. Con't. of 10/134,314	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR James A. Shayman	FILING DATE April 15, 2004	
April 15, 2004 (Use several sheets if necessary)	EXAMINER COPPINS	CONFIRMATION NO. GROUP .	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
2Ch	, AR	Abe A., et al., "Improved Inhibitors of Glucosylceramide Synthesis," J. Biochem., 111:191-196 (1992).			
	AS	Alon, R., et al., "Glycolipid Ligands for Selections Support Leukocyte Tethering & Rolling Under Physiologic Flow Conditions," J. Immunol., 154:5356-5366 (1995).			
	AT	Bielawska, A., et al., "Modulation of Cell Growth and Differentiation by Ceramide," FEBS Letters, 307:211-214 (1992).			
	AU	Blobe, G. C., et al., "Regulation of PKC and Its Role inCancer Biology," Cancer Metastasis Rev., 13:411-431 (1994).			
	AV	Felding-Habermann, B., et al., "A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosine Synthesis," Biochemistry, 29:6314-6322 (1990).			
•	AW	Gatt, S., et al., "Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids," Meth. Enzymol., 72:351-375 (1981).			
	ÀX	Hakomori, S. "New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy," Cancer Cells, 3:461-470 (1991).			
	AY	Hospattankar, A.V., et al., "Changes in Liver Lipids After Administration of 2-Decanoylamino-3-Morpholinopropiophenone and Chlorpromazine," Lipids, 17:538-543 (1982).			
	AZ	Inokuchi, J., et al., "Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis," Cancer Lett., 38:23-30 (1987).			
	AR2	Inokuchi, J., et al., "Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action," Cancer Res., 50:6731-6737 (1990).			
	AS2	Inokuchi, J., et al., "Preparation of the Active Isomer of 1-Phenyl-2-Decanoylamino-3-Morpholino-1 Propanol, Inhibitor of Glucocerebroside Synthetase," J. Lipid Res. 28:565-571 (1987).			
HC	AT2	Jaffrezou, J., et al., "Inhibition of Lysosomal acit Sphingomyelinase by Agents which Reverse Multridrug Resistance," Biochem. Biophys. Acta, 1266:1-8 (1995).			

EXAMINER DOS LYON	DATE CONSIDERED $9/2/05$
@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;46/179;1	

**				Sheet 3 of	
PŢO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3646.1001-013		APPLICATION NO. Con't. of 10/134,314		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR James A. Shayman	<u>-</u>	FILING DATE April 1	5,2004	
April 15, 2004 (Use several sheets if necessary)	EXAMINER Janet L Coppins	CONF	IRMATION NO.	GROUP 1626	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
96	AU2	Radin, N.S., et al., "Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances," In Advances in Lipid Research; Sphingolipids in Signaling, Part B., R.M. Bell et al., Ed. (Academic Press, San Diego) 28:183-213 (1993).
	AV2	Radin, N.S., et al., "Use of 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol (PDMP), an Inhibitor of Glucosylceramide Synthesis," In Neuro-Protocols, A Companion to Methods in Neurosciences, Fisher et al., Ed., (Academic Press, San Diego) 3:145-155 (1993).
	AW2	Rosenwald, A.G., et al., "Effects of the Blycosphingolipid Synthesis Inhibitor, PDMP, On Lysosomes in Cultured Cells," J. Lipid Res., 35:1232 (1994).
	AX2	Shayman, J.A., et al., "Modulation of Renal Epithelial Cell Growth by Glucosylceramide: Association with Protein Kinase C, Sphingosine, and Diacylglyceride," J. Biol. Chem., 266:22968-22974 (1991).
	AY2	Svensson, M., et al., "Ephithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production," Infect. And Immun. 62:4404-4410 (1994).
	AZ2	Zador, I.Z., et al., "A Role of Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-Induced Diabetes Mellitus," J. Clin. Invest. 91:797-803 (1993).
	AR3	Ziche, M., et al., "Angiogenesis Can be Stimulated or Repressed in In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Lab. Invest., 67:711-715 (1992).
ju		

EXAMINER	got 2 Gg	DATE CONSIDERED 9/2/05

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3646.1001-013	APPLICATION NO. 10/824,708	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	ames A. Shayman	FILING DATE April 15, 2	004
January 31, 2005 (Use several sheets if necessary)	Not yet assigned JANET	CONFIRMATION NO. 7244	GROUP 1621/626

	A MADE OF				
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
gec	AS3	CAPLUS listing of Accession No. 1985:221199, Keith McCullagh et al., "Carboxylalkyl Peptide Derivatives."			

EXAMINER DAY & CAST.

DATE CONSIDERED

9/2/05